This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Pitolisant
First-in-class histamine H3 inverse agonist from Bioprojet (EU 2016) / Harmony Biosciences (US 2019, expanded 2020 cataplexy + 2024-2025…
Aliases (5)
Overview
What is Pitolisant?
Pitolisant (Wakix, BF2.649) is a first-in-class selective histamine H3 receptor inverse agonist, FDA-approved for narcolepsy with or without cataplexy. It is the first non-stimulant non-scheduled wakefulness-promoting agent.
Key Benefits
Significantly reduces excessive daytime sleepiness and cataplexy in narcolepsy with no abuse potential and no scheduling. Used off-label for idiopathic hypersomnia, ADHD, and Parkinson's daytime sleepiness; well tolerated with non-stimulant subjective profile.
Mechanism of Action
Selective inverse agonist at presynaptic histamine H3 autoreceptors, blocking the negative feedback they exert on histaminergic neurons. This increases histamine release in the cortex and tuberomammillary nucleus, promoting wakefulness via H1 receptors.
Pharmacokinetics
▸Brand options1 known
Status"NOT a controlled substance (US, EU, most jurisdictions) — Rx-only. Notable: only FDA-approved narcolepsy treatment that is not a controlled substance."
Research Indications
Volume of distribution ~700 L (~10 L/kg)
high tissue penetration.
Metabolism: primarily CYP2D6, secondarily CYP3A4
to inactive metabolites. Renal excretion of metabolites; minimal unchanged drug.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Standard narcolepsy combination — pitolisant for daytime EDS + cataplexy, oxybate for consolidated nighttime sleep + cataplexy. Often used together clinicall…
Pitolisant + CPAP is the EU-approved use-case for residual EDS despite CPAP optimization (Ozawade brand). Demonstrated additive in HAROSA trials.
Different mechanisms (DAT/orexin/histamine cascade vs direct H3) — could be additive in modafinil-resistant narcolepsy. Not commonly stacked due to cost/redu…
May buffer mild histamine-driven anxiety without blunting wake-promotion. No direct interaction.
Supports normal QT interval (low Mg → QT prolongation risk); may reduce theoretical QT concern with pitolisant. Practically prudent stacking.
DIRECTLY COUNTERPRODUCTIVE. Pitolisant raises brain histamine to activate H1; H1 antihistamines block H1 → cancellation of the wake-promoting mechanism. The …
Less concern than sedating ones. Loratadine + fexofenadine essentially BBB-impermeable. Cetirizine is gray-zone — generally OK, monitor effect.
Paroxetine, fluoxetine, bupropion, quinidine, terbinafine, ritonavir → pitolisant exposure ↑↑, cap at 17.8 mg/day.
Rifampin, carbamazepine, phenytoin, St. John's Wort, modafinil itself (mild CYP3A4 inducer) → pitolisant exposure ↓, may lose efficacy.
Class IA/III antiarrhythmics, methadone, ondansetron at high doses, citalopram >20 mg, several macrolides + fluoroquinolones, several antipsychotics (haloper…
Both CYP2D6 inhibitor (raises pitolisant) and seizure-threshold lowerer; complicated combination, not advised.
Theoretical histamine-amine interaction; avoid pending more data.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- OnsetSlow. Tmax ~3-5 hr, but clinical effect builds over days-to-weeks, not hours. Day 1 dose at 8.9 mg often imperceptible. Many patients report no clear subjec…
- Peakexperience: Gentle, "background" wakefulness — less drive, less alertness, less edge than modafinil. The most consistent descriptor across user reports is "I…
- TaperNo crash. No rebound. Discontinuation produces gradual return of EDS over days, not abrupt wake-loss.
Side Effects & Safety 17
Side Effects
- 1Insomnia (8-9%) — biggest dose-limiter; PM/late-AM dosing risk
- 2Nausea (6%) — usually first weeks, dose-dependent
- 3Anxiety (5-7%) — histamine-driven autonomic; usually mild
- 4Headache (12-18% — occurs in pitolisant + placebo arms at similar rates in some trials, slightly elevated in others; considered drug-related at higher doses)
- 5Upper respiratory tract infection
- 6Musculoskeletal pain
- 7Increased heart rate (mild, ~3-5 bpm)
- 8Hallucinations (typically hypnagogic, more often in narcolepsy patients with baseline tendency)
- 9Irritability
- 10Abdominal pain
- 11Sleep disturbance (vivid dreams, fragmented sleep)
- 12Decreased appetite
- 13Tremor
- 14Vertigo
- 15Dyspepsia / heartburn
- 16Vomiting
- 17Depression (rare, watch for)
When to Stop
- QT interval prolongation — modest mean increase (~3-5 ms QTc at 35.6 mg) but FDA-labeled. Avoid in: known long QT syndrome, electrolyte abnormalities (low K+, low Mg2+), concurrent QT-prolonging drugs (some antiarrhythmics, some antibiotics like azithromycin/clarithromycin, some antipsychotics). Pre-dose and on-treatment ECG advisable in higher-risk populations.
- Torsades de pointes — extremely rare; theoretical concern based on QT signal.
- Spontaneous abortion — animal reproductive toxicity at high doses; pregnancy Category C-equivalent; contraceptive interaction independent risk (see Drug interactions).
- Severe weight loss — rare but reported; appetite suppression typically mild but occasionally significant.
- Mood changes / depression — rare but tracked; discontinue if persistent.
- Hepatic enzyme elevations — uncommon, usually transient.
- First 3-4 weeks (titration): Headache + insomnia + nausea most common in this window. If insomnia persists at 17.8 mg, consider holding at that dose rather than escalating to 35.6 mg.
- First 8 weeks: Anxiety, mood, appetite tracking. Many AEs that emerge early resolve by week 8.
- First ECG at 4-8 weeks if any palpitations or if patient is on other QT-prolonging drugs.
- Annual: Hepatic panel, ECG, weight check.
References
FDA Wakix Prescribing Information 2024
Full label including pediatric updates.
View StudyNCBI Clinical Review - Pitolisant Hydrochloride Wakix
Comprehensive clinical review.
View StudyPitolisant Hydrochloride NCBI Bookshelf NBK601806
Pharmacology and clinical use.
View Study2025 Updated Systematic Review and Meta-Analysis — PubMed 41324388
Pitolisant efficacy + safety in narcolepsy + OSA through August 2025.
View StudyEfficacy of Pitolisant in Narcolepsy — Systematic Review PMC8325524
Earlier systematic review.
View StudyPitolisant rationale and clinical utility in narcolepsy — PMC7567539
Clinical rationale review.
View StudyPitolisant H3 receptor antagonist review — PMC7554886
H3 antagonist class update.
View StudyPitolisant Alzheimer's mouse model — PMC11971262
Preclinical AD model showing cognitive + amyloid effects.
View StudyPitolisant abuse potential study — PMC7157189
Setnik et al. abuse potential study supporting non-controlled status.
View StudyPitolisant abuse potential evaluation — Sleep journal Oxford
Abuse liability evaluation.
View StudyPitolisant pharmacokinetics in pediatric narcolepsy — PubMed 31978866
Pediatric PK.
View StudyTime to Onset of Response Analysis — PMC8642365
When pitolisant response emerges in trials.
View StudyHormonal contraceptive interaction Neurology supplement
CYP3A4 induction + contraceptive interaction.
View StudyDrugs.com user reviews for narcolepsy
User satisfaction data (n~20, 5.2/10 average).
View StudyFDA Pitolisant Idiopathic Hypersomnia Refusal-to-File February 2025
RTF announcement.
View StudyFDA Approves Pitolisant for Pediatric EDS — NeurologyLive
2024 pediatric EDS approval.
View StudyFDA Approves Pitolisant for Pediatric Cataplexy 2025 — NeurologyLive
2025 pediatric cataplexy approval.
View StudyFDA Approves Pitolisant for Cataplexy in Narcolepsy 2020 — NeurologyLive
Adult cataplexy approval Oct 2020.
View StudyHarmony Biosciences 2026 revenue guidance
>$1B Wakix revenue guidance.
View StudyLong-term efficacy and safety interim analysis — NeurologyLive
Long-term extension data.
View StudyNetwork meta-analysis narcolepsy treatments — Sleep Oxford
Pitolisant vs other narcolepsy drugs network MA.
View StudyHistamine H3 receptor pitolisant historical review — PMC3111674
Schwartz lab origin story to clinical trials.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.